• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Tyber Medical Reaches Agreement to Acquire CatapultMD

Share:

September 27, 2021

Since its founding in 2012, Tyber Medical has experienced record growth with its continually expanding product portfolio. In support of its rapid growth, Tyber implemented a vertical integration strategy, in 2019, that included a large-scale expansion of its headquarters located in the Lehigh Valley in Pennsylvania. As Tyber Medical continues to expand its customer base and product portfolio, which includes private label orthopedic implants for the trauma, extremity, and spine markets, it will now double its manufacturing capacity upon purchasing all the assets of CatapultMD, based in Bonita Springs, Florida.

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square foot of manufacturing space between its Pennsylvania headquarters and Florida-based facilities. The acquisition will expand Tyber Medical’s machining footprint to include over 40 CNC Swiss machines and 10, 5-axis CNC mills for manufacturing plates, screws, spinal implants, and instrumentation used in orthopedic surgery.

With the receipt of two U.S. Food and Drug Administration (FDA) 510(k) clearances for its anatomical plating systems in the last year, Tyber Medical now offers its most comprehensive portfolio of products, since its founding in 2012. “We’ve been on a significant growth trajectory fueled by our expert research and development team, outstanding engineering capability, and our recent FDA clearances,” said Tyber Medical Chief Executive Officer Jeff Tyber. “Our acquisition of CatapultMD’s top-of-the-line CNC automation and inspection capabilities seamlessly aligns with our strict MDSAP and ISO 13485 quality standards and enables us to meet and exceed our growing demand by instantaneously doubling our internal manufacturing and processing capacity.”

The CatapultMD transaction is expected to add up to 24 team members to Tyber’s current workforce of 120, including the co-founders of CatapultMD, Len and Oliver Zaiser. Len Zaiser is well-known through the founding of Structure Medical and well-respected for his unique engineering talent and creativity in using state-of-the-art precision machine tools and equipment to ensure that the most complicated designs meet the highest quality standards.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“On behalf of the CatapultMD team, we are pleased that Tyber Medical will be the new owner of this business, enabling it to further flourish for the benefit of our customers and beyond,” said CatapultMD President and founder Oliver Zaiser.

The acquisition gives Tyber Medical access to the diverse customers that CatapultMD currently serves. “We are very excited to serve these medical device companies and welcome them into our Tyber Medical customer family,” said Tyber. “Our business is based on filling gaps in our customers’ product portfolios by bringing FDA-cleared, MDR-compliant, and CE-approved medical devices to market for them in less than 12 months. Our acquisition of CatapultMD will help us ensure that our integrated supply chain will continue to meet our critical speed to market metric.”

The transaction is expected to close before the end of the year.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Experian Health Launches AI-Driven Predictive Denials ManagementExperian Health Launches AI-Driven Predictive Denials Management
  • Lilly Completes Acquisition of POINT BiopharmaLilly Completes Acquisition of POINT Biopharma
  • Microsoft signs a huge deal with Walgreens, as Amazon’s growing interest in health care looms largeMicrosoft signs a huge deal with Walgreens, as Amazon’s growing interest in health care looms large
  • Alume Biosciences Completes $5.5M Series A FinancingAlume Biosciences Completes $5.5M Series A Financing
  • Cohere Health Adds $10m to Streamline Care By Connecting Providers and PayersCohere Health Adds $10m to Streamline Care By Connecting Providers and Payers
  • Can Blockchain-Enabled Telehealth Uphold the Sovereignty of Physicians?Can Blockchain-Enabled Telehealth Uphold the Sovereignty of Physicians?
  • Oncology Pharma and Ribera Solutions Signed a Licensing Agreement for the Use of Ribera’s Clinical Trials Platform, Connect2MedOncology Pharma and Ribera Solutions Signed a Licensing Agreement for the Use of Ribera’s Clinical Trials Platform, Connect2Med
  • EmblemHealth Announces Partnership with Medly Pharmacy for Prescription Home Delivery Services as COVID-19 Cases IncreaseEmblemHealth Announces Partnership with Medly Pharmacy for Prescription Home Delivery Services as COVID-19 Cases Increase

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications